阿博格 将出席 2025（第四届）高分子3D打印材料高峰论坛 （7月18-20日 | 浙江 · 杭州），并分 享 "推动颗粒料PEEK在医疗方向的增材制造的发展" 。 聚醚醚酮（PEEK） ，作为一种高端的特种工程塑料，正在经历一场由 3D打印技术 驱动的深刻变 革，其在 医疗植入 领域掀起了一场替代传统钛合金的变革浪潮。 VICTREX威格斯的PAEK 103GRA EMS艾曼斯的PA12 Grilamid TR90 PEEK医用材料为何如此重要？高性能PEEK专用料如何开发和应用？批量制造如何突破？增材制造 未来有哪些新方向？ 对此， 阿博格机械（上海）有限公司增材制造经理 季仲恺 将出席 2025（第四届）高分子3D 打印材料高峰论坛 （7月18-20日 | 浙江 · 杭州），并对 「生物3D打印」 主题专场分享题为" 推动 颗粒料PEEK在医疗方向的增材制造的发展 "的报告，欢迎行业参与交流！ PEEK在骨板应用的新进展 摸着工业应用过河是PEEK在医疗领域应用的真实写照 。目前，骨科植入和修补材料还是以金属为 主如钛合金，但其存在弹性模量高、不耐人体体液腐蚀、长期在体内会释放金属离子等问题。业内一 ...

Format: Corporate update Date/Time: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ET for registered conference attendees Location: Virtual Registration Link: Click Here About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next- generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS ...

Reviva Pharmaceuticals Reviva | Corporate Presentation 3 Phase 3 RECOVER Open-Label Extension (OLE) Trial of Brilaroxazine in Schizophrenia June 2, 2025 at 8:00am EDT Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's expectations regarding the anticipate ...

Core Insights - Reviva Pharmaceuticals announced positive results from the Phase 3 RECOVER open-label extension study of brilaroxazine for schizophrenia, demonstrating sustained efficacy and a well-tolerated safety profile over one year [1][2][5] Efficacy and Safety - Brilaroxazine showed robust broad-spectrum efficacy across all major symptom domains of schizophrenia, with a statistically significant reduction in PANSS total score of -18.1 at 12 months [3][4] - The treatment was generally well-tolerated, with a discontinuation rate of 35%, primarily due to withdrawal of consent and loss to follow-up [1][9] - Improvements in multiple neuroinflammatory markers were observed, suggesting enhanced efficacy and reduced side effects [1][2][9] Clinical Data - The study included a pooled analysis of 446 patients receiving doses of 15 mg, 30 mg, and 50 mg, showing dose-dependent efficacy [2][4] - Key findings included a reduction in negative symptoms by -4.4 at 12 months and significant improvements in personal and social performance scores [3][4] - The treatment also demonstrated a low incidence of treatment-emergent adverse events, with most being mild or moderate in severity [9][10] Future Development - Reviva aims to advance brilaroxazine towards regulatory submission, with plans to explore its use in other neuropsychiatric conditions such as bipolar disorder and major depressive disorder [10][11] - The company has received Orphan Drug Designation from the FDA for brilaroxazine in treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis [11][12]

CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences. Benchmark Healthcare House Call Virtual I ...

会打太极的人形机器人、可以背在身上的激光打印设备、1.6T光模块、500万像素红外探测仪……5月15 日至5月17日，以"光联万物、智引未来"为主题的第20届"中国光谷"国际光电子博览会(以下简称"光博 会")在中国光谷科技会展中心举办，记者在展会现场看到，多家企业集中展示光通信、激光等光电子信 息领域的最新科技成果。 "在光博会上，许多'全球首创''行业首发'亮相，全球光电子信息产业资源在这里汇聚，多家企业的产品 代表了光电子信息领域的最新技术和市场趋势。光博会已成为行业'风向标'。"国际光学委员会副主席 顾波在接受《证券日报》记者采访时表示。 智参智库特聘专家袁博在接受《证券日报》记者采访时表示，光电子信息产业在推动科技进步、产业升 级和经济发展中发挥着关键作用。我国光电子信息产业在国际上已占据领先地位，产业规模已领先欧 洲、北美、日韩等地，位列全球第一。"随着核心领域技术不断突破，且形成了国际市场的竞争力，我 国光电子信息产业正处于从规模领跑到技术引领的转型阶段。"袁博说。 "首发""首展" 成行业创新"风向标" 激光、光模块以及红外传感器是我国在光电子信息产业中具有创新先发优势的细分领域。 "本届光博 ...

Core Insights - Reviva Pharmaceuticals is advancing its late-stage brilaroxazine program towards registration, with significant upcoming milestones including the full dataset from the long-term open-label extension trial expected in Q2 2025 and the initiation of the Phase 3 RECOVER-2 trial anticipated in mid-2025 [2][4]. Clinical Program Highlights - A total of 446 participants completed the long-term open-label extension trial for brilaroxazine, with 156 completing one year and 301 completing six months of treatment [1][5]. - The full data analysis from the RECOVER OLE trial will include clinical response, safety, efficacy, adherence, and biomarker data, expected to be reported in Q2 2025 [1][5]. - The company plans to submit a New Drug Application (NDA) for brilaroxazine in the fourth quarter of 2026, targeting unmet needs in schizophrenia treatment [2][5]. Financial Results - For the first quarter ended March 31, 2025, the company reported a net loss of approximately $6.4 million, or $0.13 per share, compared to a net loss of approximately $7.4 million, or $0.25 per share, for the same period in 2024 [10][12]. - As of March 31, 2025, cash and cash equivalents totaled approximately $5.3 million, down from approximately $13.5 million as of December 31, 2024 [10][11]. Anticipated Milestones and Events - The company will present a late-breaking poster on the RECOVER 12-month OLE trial at the 2025 American Society of Clinical Psychopharmacology annual meeting on May 28, 2025 [5]. - The initiation of the registrational Phase 3 RECOVER-2 trial for brilaroxazine is expected in mid-2025, contingent on additional financing [5].

F&G Annuities & Life (FG) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Company Participants Lisa Foxworthy-Parker - SVP - Investor & External RelationsChris Blunt - CEOConor Murphy - CFO Conference Call Participants John Barnidge - Managing Director & Senior Research AnalystWes Carmichael - Senior AnalystMark Hughes - Analyst Operator Good morning, and welcome to F and G's First Quarter twenty twenty five Earnings Call. During today's presentation, all callers will be placed in a listen only mode. Followi ...

Jackson Financial (JXN) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Speaker0 for attending the Jackson Financial 1Q twenty twenty five Earnings Call. My name is Matt, and I'll be the moderator for today's call. I'd now like to pass the conference over to our host, Liz Werner, Head of Investor Relations. Liz, please go ahead. Speaker1 Good morning, everyone, and welcome to Jackson's first quarter twenty twenty five earnings call. Today's remarks may contain forward looking statements, which are subject to ...

F&G Investor Update F&G Investor Update | Spring 2025 2 Non-GAAP Financial Measures Spring 2025 Disclaimer & Forward-Looking Statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are beyond our control. Some of the forward-looking statements can be identified by the use of terms such as "believes", "expects", "may", "will", "could", "seeks", "intends", "plans", "estimates", "anticipates" or other comparable terms. Statem ...